[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE486076T1 - 6-carboxy-normorphinan-derivate, ihre synthese und verwendung - Google Patents

6-carboxy-normorphinan-derivate, ihre synthese und verwendung

Info

Publication number
ATE486076T1
ATE486076T1 AT07811067T AT07811067T ATE486076T1 AT E486076 T1 ATE486076 T1 AT E486076T1 AT 07811067 T AT07811067 T AT 07811067T AT 07811067 T AT07811067 T AT 07811067T AT E486076 T1 ATE486076 T1 AT E486076T1
Authority
AT
Austria
Prior art keywords
normorphinane
carboxy
synthesis
derivatives
normorphinane derivatives
Prior art date
Application number
AT07811067T
Other languages
English (en)
Inventor
Syed Shah
Kadum Ali
Fangming Kong
Tianmin Zhu
Charles Gombar
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of ATE486076T1 publication Critical patent/ATE486076T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07811067T 2006-08-04 2007-08-03 6-carboxy-normorphinan-derivate, ihre synthese und verwendung ATE486076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83568706P 2006-08-04 2006-08-04
PCT/US2007/017365 WO2008016704A1 (en) 2006-08-04 2007-08-03 6-carboxy-normorphinan derivatives, synthesis and uses thereof

Publications (1)

Publication Number Publication Date
ATE486076T1 true ATE486076T1 (de) 2010-11-15

Family

ID=38649979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07811067T ATE486076T1 (de) 2006-08-04 2007-08-03 6-carboxy-normorphinan-derivate, ihre synthese und verwendung

Country Status (15)

Country Link
US (1) US7501434B2 (de)
EP (1) EP2046800B1 (de)
JP (1) JP2009545629A (de)
CN (1) CN101522684A (de)
AR (1) AR062211A1 (de)
AT (1) ATE486076T1 (de)
AU (1) AU2007281408A1 (de)
BR (1) BRPI0715342A2 (de)
CA (1) CA2660027A1 (de)
CL (1) CL2007002272A1 (de)
DE (1) DE602007010151D1 (de)
MX (1) MX2009001282A (de)
PE (1) PE20080537A1 (de)
TW (1) TW200815451A (de)
WO (1) WO2008016704A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
TWI466671B (zh) * 2007-03-29 2015-01-01 Progenics Pharm Inc 末梢性類鴉片受體拮抗劑及其用途
CA2945356C (en) 2007-03-29 2021-03-23 Progenics Pharmaceuticals, Inc. (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist
EP2139890B1 (de) 2007-03-29 2014-06-25 Wyeth LLC Peripherer opioid-rezeptor antagonisten und verwendungen davon
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
AU2009265034B2 (en) 2008-07-01 2015-09-03 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3087057A4 (de) * 2013-12-26 2017-06-28 Purdue Pharma LP Ringkontrahierte morphinane und verwendung davon
CN109096190B (zh) * 2017-06-21 2021-07-02 中国医学科学院药物研究所 一种青藤碱衍生物及其制备方法、用途和药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
IT1269826B (it) 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
AU2003290630B2 (en) 2002-11-08 2009-01-29 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2101773A2 (de) 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomere von 7,8-gesättigten-4,5-epoxy-morphinanium-analoga
MX2009005461A (es) 2006-11-22 2009-08-28 Progenics Pharm Inc N-oxidos de analogos de 4,5-epoxi-morfinano.
CN101636400A (zh) 2006-11-22 2010-01-27 普罗基因制药公司 用于合成季4,5-环氧-吗啡烷类似物以及分离出它们的n-立体异构体的方法
TWI466671B (zh) 2007-03-29 2015-01-01 Progenics Pharm Inc 末梢性類鴉片受體拮抗劑及其用途
EP2139890B1 (de) 2007-03-29 2014-06-25 Wyeth LLC Peripherer opioid-rezeptor antagonisten und verwendungen davon

Also Published As

Publication number Publication date
US20080064744A1 (en) 2008-03-13
BRPI0715342A2 (pt) 2015-03-24
WO2008016704A1 (en) 2008-02-07
CL2007002272A1 (es) 2008-04-18
AU2007281408A1 (en) 2008-02-07
PE20080537A1 (es) 2008-06-23
EP2046800B1 (de) 2010-10-27
TW200815451A (en) 2008-04-01
MX2009001282A (es) 2009-02-11
CA2660027A1 (en) 2008-02-07
DE602007010151D1 (de) 2010-12-09
JP2009545629A (ja) 2009-12-24
AR062211A1 (es) 2008-10-22
CN101522684A (zh) 2009-09-02
EP2046800A1 (de) 2009-04-15
US7501434B2 (en) 2009-03-10

Similar Documents

Publication Publication Date Title
ATE486076T1 (de) 6-carboxy-normorphinan-derivate, ihre synthese und verwendung
ATE540952T1 (de) Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE548355T1 (de) 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
BRPI0818373A2 (pt) compostos de pelicetal, síntese e aplicações
DK1868967T3 (da) Kulbrintesyntese
ATE517886T1 (de) Pyrazolderivate
ATE487691T1 (de) Acetylenderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
NL2000527A1 (nl) Dibenzylamine-verbindingen en -derivaten.
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE544752T1 (de) Aryloxyacetamidderivate und ihre verwendung als fungizide
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE413389T1 (de) Chinazolinderivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
DK1971588T3 (da) Tiglien-3-onderivater
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE451923T1 (de) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid- derivate, ihre herstellung und verwendung
ATE513817T1 (de) Pyrimidinderivate und ihre verwendung als pestizide
DE602006000612D1 (de) Beidseitig tragbare Orthese
HK1136159A1 (en) Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use
DE602006014973D1 (de) Neuartige cercosporamidderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties